About Us

Truvian Sciences was founded in 2015 by individuals with deep domain experience in healthcare, diagnostics, and consumer technology. Today, the team has expanded to include top scientists, engineers, and healthcare business leaders – each bringing specialized expertise to drive Truvian’s mission. Together, we are disrupting the blood testing industry to fulfill an unmet need, developing an automated benchtop FDA-cleared system that allows practitioners to deliver data to patients instantaneously on a secure and easy-to-use mobile platform.

Executive Leadership

Jeff Hawkins

President and Chief Executive Officer

Katherine Atkinson

Senior Vice President, Sales and Support

Dena Marrinucci Ph.D.

Co-Founder and Chief Operating Officer

For almost 20 years, Mr. Hawkins has held executive and management roles at the world’s leading healthcare companies. Specializing in the advancement of life-changing technologies, Mr. Hawkins joined Truvian Sciences as President and Chief Executive Officer in January 2018. Prior to Truvian, Mr. Hawkins was Vice President and General Manager of the Reproductive and Genetic Health Business at Illumina, Inc. Before Illumina, he served as Senior Vice President of Global Marketing and Program Management for GenMark Diagnostics. Previously, Mr. Hawkins held roles of increasing responsibility in business development for Hologic, Third Wave Technologies and Abbott Laboratories. Mr. Hawkins holds a B.A. in Chemistry with honors from Concordia University and an M.B.A. from Keller Graduate School of Management.

Ms. Atkinson has more than 20 years of experience in the healthcare and life sciences industries, where she continuously creates customer-focused teams that achieve and exceed global commercial and sales goals. Prior to joining Truvian, Ms. Atkinson served as Epic Sciences’ Chief Commercial Officer, where she identified new strategic business opportunities and deepened existing strategic partnerships. Prior to Epic, Ms. Atkinson was Vice President of Business Development and Strategic partnerships at Edico Genome. Previously, she held roles of increasing responsibility at Illumina, including as Commercial Director of Global Channel Partners and Director, Global Channel Partners, LATAM & Inside Sales, Demand Generation and Product Care Teams. Ms. Atkinson’s previous experience also includes leadership roles at Fisher Scientific, Thermo Fisher and Beckman Coulter. She holds a B.A in Broadcast Journalism and Public Speaking from the University of Houston.

Dr. Marrinucci is a life science entrepreneur with a passion for introducing diagnostic technologies with potential to transform human health. She co-founded Truvian in late 2015 and leads research, operations, program management and strategic partnerships for the company. Prior to founding Truvian, Dr. Marrinucci founded Epic Sciences in 2008 and was the company’s Chief Scientific Officer. During her tenure at Epic, Dr. Marrinucci developed a novel circulating tumor cell technology and helped grow the company, overseeing its diagnostic collaborations with pharmaceutical companies and developing its clinical laboratory and assay development operations.

Dr. Marrinucci has been named to MIT Technology Review’s 35 Innovators Under 35, Foreign Policy’s Top 100 Leading Global Thinkers, PharmaVoice 100’s Top Entrepreneurs, The Daily Transcript’s 40 Under 40 Business Professionals, San Diego Business Journal’s Most Influential Women in Technology, and Stella Labs’ Entrepreneur of the Year. She was also named a 2016 Life Science Catalyst Award winner, has authored dozens of peer reviewed publications and is an inventor on 12 patents. Dr. Marrinucci also serves as an Advisor for Lynx Biosciences, a cancer diagnostic company. She holds a B.S. in Chemistry from the University of Vermont and a Ph.D. in Chemical Biology from The Scripps Research Institute.

Karen Smith

Vice President, People and Culture

Jay Srinivasan

Chief Product Officer

Vernon Trimble

Senior Vice President, Regulatory and Quality

As a highly accomplished and progressive human resources executive with expertise across biotech, technology, advertising, and financial services industries, Ms. Smith has over 20 years of experience managing all aspects of human resources. Prior to joining Truvian, she led HR teams for companies ranging from 100 – 4500 employees at LPL Financial, Encore Capital Group, Verve, and The Heraeus Group. Ms. Smith holds a B.S. in Human Behavior/Family Studies and Psychology from the University of Arizona. She completed the Strategic Human Resources Management Program from Cornell University and International Management Program from University of St. Gallen in Switzerland. Ms. Smith has served on the boards of professional associations and non-profits to support the next generation of HR professionals.

For almost 15 years, Mr. Srinivasan has held executive and management roles at the world’s leading healthcare companies. Prior to joining Truvian, Mr. Srinivasan was Divisional Vice President at Abbott Laboratories, where he was responsible for product software, automation and informatics. Before Abbott, he served as Vice President, Next Generation Platforms for GenMark Diagnostics. Mr. Srinivasan has also held various leadership roles in systems development at Danaher (Beckman Coulter) and Qiagen (Digene). He holds a B.E. in Electrical Engineering from the National Institute of Technology (India), a M.S. in Biomedical Engineering from Drexel University, and a M.B.A. from Northwestern University’s Kellogg School of Management. Mr. Srinivasan currently sits on the Industry Advisory Board for the School of Biomedical Engineering at Colorado State University.

Mr. Trimble has over 25 years of experience in the medical device and pharmaceutical industries, where he provided strategic leadership for regulatory strategy, agency interactions, and product submissions. Prior to joining Truvian, Mr. Trimble served as the Vice President of Regulatory Affairs, Quality Assurance, and Global Trade Compliance in Thermo Fisher Scientific’s Clinical Diagnostic Division. Prior to Thermo Fisher, Mr. Trimble held executive roles at Alphatec Spine, Respironics (acquired by Philips Healthcare), and Smiths Medical. He holds an M.B.A. from Maryville University and a M.S. in Regulatory Affairs from San Diego State University.

Jeff Hawkins

President and Chief Executive Officer

For almost 20 years, Mr. Hawkins has held executive and management roles at the world’s leading healthcare companies. Specializing in the advancement of life-changing technologies, Mr. Hawkins joined Truvian Sciences as President and Chief Executive Officer in January 2018. Prior to Truvian, Mr. Hawkins was Vice President and General Manager of the Reproductive and Genetic Health Business at Illumina, Inc. Before Illumina, he served as Senior Vice President of Global Marketing and Program Management for GenMark Diagnostics. Previously, Mr. Hawkins held roles of increasing responsibility in business development for Hologic, Third Wave Technologies and Abbott Laboratories. Mr. Hawkins holds a B.A. in Chemistry with honors from Concordia University and an M.B.A. from Keller Graduate School of Management.

Katherine Atkinson

Senior Vice President, Sales and Support

Ms. Atkinson has more than 20 years of experience in the healthcare and life sciences industries, where she continuously creates customer-focused teams that achieve and exceed global commercial and sales goals. Prior to joining Truvian, Ms. Atkinson served as Epic Sciences’ Chief Commercial Officer, where she identified new strategic business opportunities and deepened existing strategic partnerships. Prior to Epic, Ms. Atkinson was Vice President of Business Development and Strategic partnerships at Edico Genome. Previously, she held roles of increasing responsibility at Illumina, including as Commercial Director of Global Channel Partners and Director, Global Channel Partners, LATAM & Inside Sales, Demand Generation and Product Care Teams. Ms. Atkinson’s previous experience also includes leadership roles at Fisher Scientific, Thermo Fisher and Beckman Coulter. She holds a B.A in Broadcast Journalism and Public Speaking from the University of Houston.

Dena Marrinucci Ph.D.

Co-Founder and Chief Operating Officer

Dr. Marrinucci is a life science entrepreneur with a passion for introducing diagnostic technologies with potential to transform human health. She co-founded Truvian in late 2015 and leads research, operations, program management and strategic partnerships for the company. Prior to founding Truvian, Dr. Marrinucci founded Epic Sciences in 2008 and was the company’s Chief Scientific Officer. During her tenure at Epic, Dr. Marrinucci developed a novel circulating tumor cell technology and helped grow the company, overseeing its diagnostic collaborations with pharmaceutical companies and developing its clinical laboratory and assay development operations.

Dr. Marrinucci has been named to MIT Technology Review’s 35 Innovators Under 35, Foreign Policy’s Top 100 Leading Global Thinkers, PharmaVoice 100’s Top Entrepreneurs, The Daily Transcript’s 40 Under 40 Business Professionals, San Diego Business Journal’s Most Influential Women in Technology, and Stella Labs’ Entrepreneur of the Year. She was also named a 2016 Life Science Catalyst Award winner, has authored dozens of peer reviewed publications and is an inventor on 12 patents. Dr. Marrinucci also serves as an Advisor for Lynx Biosciences, a cancer diagnostic company. She holds a B.S. in Chemistry from the University of Vermont and a Ph.D. in Chemical Biology from The Scripps Research Institute.

Karen Smith

Vice President, People and Culture

As a highly accomplished and progressive human resources executive with expertise across biotech, technology, advertising, and financial services industries, Ms. Smith has over 20 years of experience managing all aspects of human resources. Prior to joining Truvian, she led HR teams for companies ranging from 100 – 4500 employees at LPL Financial, Encore Capital Group, Verve, and The Heraeus Group. Ms. Smith holds a B.S. in Human Behavior/Family Studies and Psychology from the University of Arizona. She completed the Strategic Human Resources Management Program from Cornell University and International Management Program from University of St. Gallen in Switzerland. Ms. Smith has served on the boards of professional associations and non-profits to support the next generation of HR professionals.

Jay Srinivasan

Chief Product Officer

For almost 15 years, Mr. Srinivasan has held executive and management roles at the world’s leading healthcare companies. Prior to joining Truvian, Mr. Srinivasan was Divisional Vice President at Abbott Laboratories, where he was responsible for product software, automation and informatics. Before Abbott, he served as Vice President, Next Generation Platforms for GenMark Diagnostics. Mr. Srinivasan has also held various leadership roles in systems development at Danaher (Beckman Coulter) and Qiagen (Digene). He holds a B.E. in Electrical Engineering from the National Institute of Technology (India), a M.S. in Biomedical Engineering from Drexel University, and a M.B.A. from Northwestern University’s Kellogg School of Management. Mr. Srinivasan currently sits on the Industry Advisory Board for the School of Biomedical Engineering at Colorado State University.

Vernon Trimble

Senior Vice President, Regulatory and Quality

Mr. Trimble has over 25 years of experience in the medical device and pharmaceutical industries, where he provided strategic leadership for regulatory strategy, agency interactions, and product submissions. Prior to joining Truvian, Mr. Trimble served as the Vice President of Regulatory Affairs, Quality Assurance, and Global Trade Compliance in Thermo Fisher Scientific’s Clinical Diagnostic Division. Prior to Thermo Fisher, Mr. Trimble held executive roles at Alphatec Spine, Respironics (acquired by Philips Healthcare), and Smiths Medical. He holds an M.B.A. from Maryville University and a M.S. in Regulatory Affairs from San Diego State University.

Board of Directors

Kim Kamdar, Ph.D.

Megh Gupta

Jeff Hawkins

Ashok Krishnamurthi

Dr. Kamdar is a Partner with Domain Associates, a healthcare venture capital leader. With a background in small molecule drug discovery, she has been involved in cutting-edge therapeutic start-ups and has been a major part of identifying companies with promising molecular and companion diagnostics to support personalized medicine. Dr. Kamdar is currently Chair of the Board of Directors of Obalon Therapeutics and serves on the boards of Epic Sciences, Evofem Biosciences, Omniome and Sera Prognostics. She is also a board member of San Diego’s CONNECT Foundation and an advisory board member of Eric Topol’s NIH-supported Clinical and Translational Science Award for Scripps Medicine.

Dr. Kamdar is the author of 10 papers as well as the inventor on seven patents. She received her B.A. from Northwestern University and her Ph.D. in Biochemistry and Genetics from Emory University.

Mr. Gupta is a Partner at Wittington Ventures, a Toronto-based venture capital firm, where he focuses on the future of healthcare. As an operator and investor, he has spent his career at the intersection of technology and investing. Mr. Gupta was the former Global Head of Strategy and Corporate Development at Element AI, where he led their $150M Series B. Prior to that, he was an investor at OMERS Ventures, where he developed an investment thesis around commercializing applications of AI. Mr. Gupta was an early member of Torstar Digital, the corporate venture and innovation arm for Torstar, where he acquired and incubated a portfolio of more than ten digital businesses.

Mr. Gupta received an M.B.A from the Kellogg School of Management and an H.B.A. from the Richard Ivey School of Business. He holds a C.P.A. accounting designation.

For almost 20 years, Mr. Hawkins has held executive and management roles at the world’s leading healthcare companies. Specializing in the advancement of life-changing technologies, Mr. Hawkins joined Truvian Sciences as President and Chief Executive Officer in January 2018. Prior to Truvian, Mr. Hawkins was Vice President and General Manager of the Reproductive and Genetic Health Business at Illumina, Inc. Before Illumina, he served as Senior Vice President of Global Marketing and Program Management for GenMark Diagnostics. Previously, Mr. Hawkins held roles of increasing responsibility in business development for Hologic, Third Wave Technologies and Abbott Laboratories. Mr. Hawkins holds a B.A. in Chemistry with honors from Concordia University and an M.B.A. from Keller Graduate School of Management.

Mr. Krishnamurthi is Managing Partner at Greatpoint Ventures, a California-based venture capital firm. A serial entrepreneur and investor, Mr. Krishnamurthi is focused on enterprise IT, and the intersection of computer science and life sciences. He founded two medical related companies – CAPP Medical, a liquid biopsy company for cancer diagnosis (sold to Roche Diagnostics), and CiberMed which focuses on biomarker discovery. He is currently a Board member of Activ Surgical, EVEN Financial, Insight-rx, Namogoo, Recogni and Scoredata.

Mr. Krishnamurthi has a B.S. in Electrical Engineering from Manipal Institute of Technology and a M.S. in Computer Engineering from Syracuse University.

Kim Kamdar, Ph.D.

Dr. Kamdar is a Partner with Domain Associates, a healthcare venture capital leader. With a background in small molecule drug discovery, she has been involved in cutting-edge therapeutic start-ups and has been a major part of identifying companies with promising molecular and companion diagnostics to support personalized medicine. Dr. Kamdar is currently Chair of the Board of Directors of Obalon Therapeutics and serves on the boards of Epic Sciences, Evofem Biosciences, Omniome and Sera Prognostics. She is also a board member of San Diego’s CONNECT Foundation and an advisory board member of Eric Topol’s NIH-supported Clinical and Translational Science Award for Scripps Medicine.

Dr. Kamdar is the author of 10 papers as well as the inventor on seven patents. She received her B.A. from Northwestern University and her Ph.D. in Biochemistry and Genetics from Emory University.

Megh Gupta

Mr. Gupta is a Partner at Wittington Ventures, a Toronto-based venture capital firm, where he focuses on the future of healthcare. As an operator and investor, he has spent his career at the intersection of technology and investing. Mr. Gupta was the former Global Head of Strategy and Corporate Development at Element AI, where he led their $150M Series B. Prior to that, he was an investor at OMERS Ventures, where he developed an investment thesis around commercializing applications of AI. Mr. Gupta was an early member of Torstar Digital, the corporate venture and innovation arm for Torstar, where he acquired and incubated a portfolio of more than ten digital businesses.

Mr. Gupta received an M.B.A from the Kellogg School of Management and an H.B.A. from the Richard Ivey School of Business. He holds a C.P.A. accounting designation.

Jeff Hawkins

For almost 20 years, Mr. Hawkins has held executive and management roles at the world’s leading healthcare companies. Specializing in the advancement of life-changing technologies, Mr. Hawkins joined Truvian Sciences as President and Chief Executive Officer in January 2018. Prior to Truvian, Mr. Hawkins was Vice President and General Manager of the Reproductive and Genetic Health Business at Illumina, Inc. Before Illumina, he served as Senior Vice President of Global Marketing and Program Management for GenMark Diagnostics. Previously, Mr. Hawkins held roles of increasing responsibility in business development for Hologic, Third Wave Technologies and Abbott Laboratories. Mr. Hawkins holds a B.A. in Chemistry with honors from Concordia University and an M.B.A. from Keller Graduate School of Management.

Ashok Krishnamurthi

Mr. Krishnamurthi is Managing Partner at Greatpoint Ventures, a California-based venture capital firm. A serial entrepreneur and investor, Mr. Krishnamurthi is focused on enterprise IT, and the intersection of computer science and life sciences. He founded two medical related companies – CAPP Medical, a liquid biopsy company for cancer diagnosis (sold to Roche Diagnostics), and CiberMed which focuses on biomarker discovery. He is currently a Board member of Activ Surgical, EVEN Financial, Insight-rx, Namogoo, Recogni and Scoredata.

Mr. Krishnamurthi has a B.S. in Electrical Engineering from Manipal Institute of Technology and a M.S. in Computer Engineering from Syracuse University.

Paul Meister

Mr. Meister brings over three decades of experience to Truvian’s board, serving in senior executive and board roles for high-growth and publicly traded companies. Most recently, Mr. Meister served as President of MacAndrews & Forbes Incorporated, a private company that owns or controls a diverse set of companies, including Revlon, Scientific Games, Harlan Clarke Corp., and SIGA Technologies. Prior to that role, he was Chairman and CEO of inVentiv Health (now Syneos Health) and Chairman of the Board at Thermo Fisher Scientific. Mr. Meister co-founded Liberty Lane Partners, LLC, a private investment company and Perspecta Trust, a trust company that provides trust and investment services. He is currently Director of the boards at Arbor Biotechnologies, Inc., Core & Main LP, Magnolia Medical Technologies, Inc., PharmaLegacy Laboratories (Shanghai) Co., Ltd., Quanterix Corporation, Revlon, Inc., Scientific Games Corporation and Wheelabrator Technologies Holdings Inc., as well as Vice Chairman at The General Chemical Group.

Mr. Meister holds a B.A. from the University of Michigan and a M.B.A from Northwestern University’s Kellogg School of Management.

Jean-Pierre "JP" Millon

Mr. Millon brings decades of experience, expertise and leadership in the healthcare and life science industries to Truvian’s board. He is currently a director at CVS Health, Inc., a role to which he was appointed in 2007 and one that has evolved as a result of the CVS merger with Caremark in April 2007 and Caremark’s purchase of AdvancePCS, a pharmacy benefit management company, in March 2004. Before his post with Caremark, Millon was named to the board of AdvancePCS in 2000 upon the merger of Advance Paradigm and PCS Health Systems. Prior to that, he was president and chief executive officer of PCS from 1996 to 2000, and also served as an executive and held several global leadership positions over the span of two decades with Eli Lilly and Company.

Millon serves on a number of healthcare company boards, including InanoBio Inc., Curemetrix, Equality Health and Valenz, and is also on the advisory boards of several companies, including Sky Republic, Kazuhm and Curematch. The latter two are incubated by Analytics Ventures, where he is also an advisor.

Millon earned a degree in mechanical engineering from Ecole Centrale de Lyon, France, and a degree in economics from the University of Lyon, France. He was awarded a Master’s of Business Administration in finance from the Kellogg School of Management at Northwestern University. He is a trustee of Scottsdale Arts and a board member of ASU Biodesign Institute.

Glen Tullman

Mr. Tullman is the Executive Chairman and CEO of Transcarent, the first comprehensive, consumer-directed health and care platform for employees of self-insured employers and their families. Born in Silicon Valley, Transcarent’s platform empowers consumers with the kind of information, guidance, and access that leads to better care, better outcomes, and more cost-effective decisions for everyone.

Mr. Tullman is the Founder and former Executive Chairman and CEO of Livongo Health, the first at-scale consumer digital health company to truly empower people with chronic conditions to live better and healthier lives using data science.

In his final year, Mr. Tullman led Livongo through the largest consumer digital health IPO in history, a secondary offering, a convertible debt offering that raised over $550 million, and the industry’s largest merger to date between Livongo and Teladoc Health, valuing Livongo at $18.5 billion and beginning a new era of consumer-centric virtual care.

A visionary leader and entrepreneur, Mr. Tullman previously ran two other public companies that changed the way healthcare is delivered. During his time as CEO of Allscripts, the Company was the leading provider of electronic prescribing, practice management, and electronic health records. Mr. Tullman led Allscripts IPO and Secondary offerings. Prior to Allscripts, he was CEO of Enterprise Systems, which he also took public and then sold to McKesson/HBOC. Before entering healthcare, Mr. Tullman served as President and COO of CCC Information Systems, a provider of computerized systems for the property and casualty insurance sector.

Mr. Tullman is one of two Founding Partners at 7wireVentures, one of the highest-returning venture capital funds in Illinois. He is the author of On Our Terms: Empowering the New Health Consumer, in which he proposes new solutions to address the chronic-condition epidemic facing our country.

Mr. Tullman is dedicated to finding a cure for diabetes and other chronic conditions—and to keeping people healthy until these cures are found. A strong proponent of philanthropy, he was honored in 2019 with a Robert F. Kennedy Human Rights Ripple of Hope Award for his career focused on improving the safety, empathy, and efficiency of our healthcare system. He also serves as a Chancellor to the International Board of the Juvenile Diabetes Research Foundation and as a Board Member of the American Diabetes Association. Mr. Tullman has three amazing children that inspire him every day.

Greg Wasson

Mr. Wasson is the former President and CEO of Walgreens Boots Alliance, Inc. As President and CEO, he led the Fortune 35 company to record fiscal 2014 sales of $76.4 billion. Mr. Wasson is recognized throughout the drugstore and healthcare industry for transformational leadership, innovation, bold business moves, and executing strategic long-term vision. After retiring, Mr. Wasson founded Wasson Enterprise, a family office that partners to build sustainable, high-growth businesses that do well by doing good. Additionally, he co-founded and is the Chairman of CoolerScreens, an innovative in-store digital marketing and merchandising platform transforming retail point of sale media, and is the Chairman of iA, a leading-edge provider of software enabled pharmacy automation solutions. Mr. Wasson also serves on the boards of Health Care Service Corporation (HCSC), OptimizeRx, Argo Tea, Reliefband, Performance Health Systems, Innventure, The Economic Club of Chicago, Corporate Leadership Center, and AUSL.

Paul Meister

Jean-Pierre "JP" Millon

Glen Tullman

Greg Wasson

Mr. Meister brings over three decades of experience to Truvian’s board, serving in senior executive and board roles for high-growth and publicly traded companies. Most recently, Mr. Meister served as President of MacAndrews & Forbes Incorporated, a private company that owns or controls a diverse set of companies, including Revlon, Scientific Games, Harlan Clarke Corp., and SIGA Technologies. Prior to that role, he was Chairman and CEO of inVentiv Health (now Syneos Health) and Chairman of the Board at Thermo Fisher Scientific. Mr. Meister co-founded Liberty Lane Partners, LLC, a private investment company and Perspecta Trust, a trust company that provides trust and investment services. He is currently Director of the boards at Arbor Biotechnologies, Inc., Core & Main LP, Magnolia Medical Technologies, Inc., PharmaLegacy Laboratories (Shanghai) Co., Ltd., Quanterix Corporation, Revlon, Inc., Scientific Games Corporation and Wheelabrator Technologies Holdings Inc., as well as Vice Chairman at The General Chemical Group.

Mr. Meister holds a B.A. from the University of Michigan and a M.B.A from Northwestern University’s Kellogg School of Management.

Mr. Millon brings decades of experience, expertise and leadership in the healthcare and life science industries to Truvian’s board. He is currently a director at CVS Health, Inc., a role to which he was appointed in 2007 and one that has evolved as a result of the CVS merger with Caremark in April 2007 and Caremark’s purchase of AdvancePCS, a pharmacy benefit management company, in March 2004. Before his post with Caremark, Millon was named to the board of AdvancePCS in 2000 upon the merger of Advance Paradigm and PCS Health Systems. Prior to that, he was president and chief executive officer of PCS from 1996 to 2000, and also served as an executive and held several global leadership positions over the span of two decades with Eli Lilly and Company.

Millon serves on a number of healthcare company boards, including InanoBio Inc., Curemetrix, Equality Health and Valenz, and is also on the advisory boards of several companies, including Sky Republic, Kazuhm and Curematch. The latter two are incubated by Analytics Ventures, where he is also an advisor.

Millon earned a degree in mechanical engineering from Ecole Centrale de Lyon, France, and a degree in economics from the University of Lyon, France. He was awarded a Master’s of Business Administration in finance from the Kellogg School of Management at Northwestern University. He is a trustee of Scottsdale Arts and a board member of ASU Biodesign Institute.

Mr. Tullman is the Executive Chairman and CEO of Transcarent, the first comprehensive, consumer-directed health and care platform for employees of self-insured employers and their families. Born in Silicon Valley, Transcarent’s platform empowers consumers with the kind of information, guidance, and access that leads to better care, better outcomes, and more cost-effective decisions for everyone.

Mr. Tullman is the Founder and former Executive Chairman and CEO of Livongo Health, the first at-scale consumer digital health company to truly empower people with chronic conditions to live better and healthier lives using data science.

In his final year, Mr. Tullman led Livongo through the largest consumer digital health IPO in history, a secondary offering, a convertible debt offering that raised over $550 million, and the industry’s largest merger to date between Livongo and Teladoc Health, valuing Livongo at $18.5 billion and beginning a new era of consumer-centric virtual care.

A visionary leader and entrepreneur, Mr. Tullman previously ran two other public companies that changed the way healthcare is delivered. During his time as CEO of Allscripts, the Company was the leading provider of electronic prescribing, practice management, and electronic health records. Mr. Tullman led Allscripts IPO and Secondary offerings. Prior to Allscripts, he was CEO of Enterprise Systems, which he also took public and then sold to McKesson/HBOC. Before entering healthcare, Mr. Tullman served as President and COO of CCC Information Systems, a provider of computerized systems for the property and casualty insurance sector.

Mr. Tullman is one of two Founding Partners at 7wireVentures, one of the highest-returning venture capital funds in Illinois. He is the author of On Our Terms: Empowering the New Health Consumer, in which he proposes new solutions to address the chronic-condition epidemic facing our country.

Mr. Tullman is dedicated to finding a cure for diabetes and other chronic conditions—and to keeping people healthy until these cures are found. A strong proponent of philanthropy, he was honored in 2019 with a Robert F. Kennedy Human Rights Ripple of Hope Award for his career focused on improving the safety, empathy, and efficiency of our healthcare system. He also serves as a Chancellor to the International Board of the Juvenile Diabetes Research Foundation and as a Board Member of the American Diabetes Association. Mr. Tullman has three amazing children that inspire him every day.

Mr. Wasson is the former President and CEO of Walgreens Boots Alliance, Inc. As President and CEO, he led the Fortune 35 company to record fiscal 2014 sales of $76.4 billion. Mr. Wasson is recognized throughout the drugstore and healthcare industry for transformational leadership, innovation, bold business moves, and executing strategic long-term vision. After retiring, Mr. Wasson founded Wasson Enterprise, a family office that partners to build sustainable, high-growth businesses that do well by doing good. Additionally, he co-founded and is the Chairman of CoolerScreens, an innovative in-store digital marketing and merchandising platform transforming retail point of sale media, and is the Chairman of iA, a leading-edge provider of software enabled pharmacy automation solutions. Mr. Wasson also serves on the boards of Health Care Service Corporation (HCSC), OptimizeRx, Argo Tea, Reliefband, Performance Health Systems, Innventure, The Economic Club of Chicago, Corporate Leadership Center, and AUSL.